Genética da doença de Parkinson no Brasil: revisão sistemática de formas monogênicas

Arq Neuropsiquiatr anp Arquivos de Neuro-Psiquiatria Arq. Neuro-Psiquiatr. 0004-282X 1678-4227 Academia Brasileira de Neurologia - ABNEURO RESUMO Introdução: Um número crescente de mutações causando formas monogênicas de doença de Parkinson (DP) tem sido descrito, principalmente entre pacientes da Europa e da América do Norte. Como a arquitetura genética varia entre diferentes populações, entender os perfis genéticos específicos de pacientes brasileiros é essencial para um melhor aconselhamento genético e para a seleção de participantes para ensaios clínicos. Objetivo: Revisão sistemática para identificar estudos genéticos brasileiros na área e definir o cenário para estudos futuros das formas monogênicas de DP no Brasil. Métodos: Nós pesquisamos as bases de dados MEDLINE, EMBASE e Web of Science desde a criação até dezembro de 2019, usando termos para “Parkinson’s disease”, “genetics” e “Brazil”. A extração de dados foi feita por dois revisores independentes. Para os genes LRRK2 e PRKN, calculamos a prevalência estimada para cada estudo e realizamos uma meta-análise. Resultados: Um total de 32 estudos foram incluídos e 94 pacientes brasileiros com DP com mutações causativas foram identificados em 2872 pacientes avaliados (3.2%). As mutações no PRKN causaram DP em 48 de 576 pacientes (8.3%). As mutações no LRRK2 foram identificadas em 40 de 1566 pacientes (2.5%), sendo a mutação mais comum a p.G2019S (2.2%). Conclusões: As mutações na PRKN são a causa mais comum de DP autossômica recessiva, e as mutações no LRRK2 a causa mais comum de DP autossômica dominante. Nós observamos uma falta de estudos epidemiológicos robustos em genética de DP, especialmente por não levar em conta a diversidade de nossa população. INTRODUCTION Over recent decades, mutations in several genes have been linked to inherited forms of Parkinson’s disease (PD). After alpha-synuclein gene (SNCA) mutations were reported to be a monogenic cause of parkinsonism1, several other genetic forms of the disease were described, including those with autosomal dominant inheritance, such as with the genes LRRK2, SNCA, VPS35, ATXN2 and GCH1, and others with recessive inheritance, such as with the genes PRKN, PINK1 and DJ1. Some other autosomal recessive mutations cause atypical parkinsonism, such as with the genes ATP13A2, PLA2G6, SYNJ1, SPG11, FBXO7 and VPS13C. Mutations in the X-linked RAB39B gene have also been described as causing parkinsonism1. Some of these mutations, such as the LRRK2 point mutation c.6055G>A (p.G2019S), are highly population-specific. While virtually absent among Asians and with low prevalence in Europeans (1-4% of sporadic PD and up to 14% of familial PD cases), LRRK2 mutations can be found in up to 28% of Ashkenazi Jewish and 38% of North-African Arab patients2. Brazil is the fifth most populous country in the world, with more than 210 million inhabitants; approximately 14% of the population is aged 60 years or over, and it has been estimated that this proportion will rise to 32% by 20603. The Brazilian population has significant genetic variability due to the interactions between Amerindian populations, Portuguese settlers and enslaved African people starting at the beginning of the 16th century; and subsequent interactions with individuals who migrated from other nations (like Italians, Japanese and Germans) in the 19th century4. Because of this genetic diversity, the frequency of different monogenic causes of PD can differ from those observed in other regions of the world. This can also vary significantly according to the different regions of the country and between socioeconomic classes. To identify these gaps in knowledge and lay the foundation for future projects in this country, we conducted a systematic review of previously published studies on monogenic forms of PD among Brazilian patients. Our aims were to provide a broad view of studies describing genetic forms of PD in Brazilian patients, and to perform a meta-analysis to estimate the prevalences of the better-explored monogenic PD mutations in Brazil. METHODS Search strategy We conducted a systematic search of the literature in MEDLINE, EMBASE and Web of Science (from inception to December 2019) using the following algorithms: MEDLINE - “Parkinson’s disease” AND Brazil AND genetics; EMBASE - (‘parkinson disease’/exp OR ‘parkinson disease’) AND (‘brazil’/exp OR brazil) AND (‘genetics’/exp OR genetics); Web of Science - ALL=(“Parkinson’s disease” AND Brazil AND genetics). Reference lists of studies that were included were checked to identify any additional studies that might have been missed in the primary search (cross-reference search). Study selection We aimed to select any original research study describing Brazilian patients with monogenic forms of PD. Two rounds of selection were performed. In the first round, titles and abstracts were screened and exclusions were made based on these exclusion criteria: (1) studies without a description of the genetic forms of PD in Brazilian patients; (2) studies not conducted on human subjects; and (3) duplicated articles. In the second round, full texts were evaluated and exclusions were made based on other exclusion criteria: (1) review studies; (2) studies on cases of patients with genetic forms of PD that had already described, without making any new contributions; (3) studies assessing different conditions (such as atypical parkinsonism or dementia with Lewy bodies); (4) conference abstracts; and (5) full text not found. Two reviewers performed each selection round independently and disagreements were resolved by reaching a consensus. The potential pathogenicity of the variants reported was assessed based on the methodology of the International Parkinson Disease and Movement Disorder Society Genetic Mutation Database (https://www.mdsgene.org/methods)5 and on the ClinVar database of the National Institute of Health, USA (https://www.ncbi.nlm.nih.gov/clinvar/)6. Data extraction Two independent reviewers extracted the data using a spreadsheet, in which the following items were reported: (1) first author’s name; (2) year of publication; (3) Brazilian region involved in the study; (4) study design; (5) studies with family history as an inclusion criteria for patients (defined as any positive family history); (6) studies with early-onset PD (EOPD) as an inclusion criteria (cutoff age at onset ranging from 40 to 55 years between studies); (7) sample size, sex and age of the study population (patients and controls); (7) genes analyzed; (8) number of mutations described; and (9) zygosity of mutations. Statistical analysis The number and prevalence of mutations in genes described in Brazilian patients with PD were calculated. We considered that PRKN and LRRK2 were the genes most explored in studies and, hence, we proceeded with further analyses on mutations in these genes. For these analyses, we excluded family case studies and case reports/series due to the high possibility of selection bias. A random-effects model was used to estimate the weighted pooled prevalence of mutations in PRKN and LRRK2. To assess the heterogeneity between the studies, the I2 test was used, and I2 above 75% was taken to indicate high heterogeneity. The analyses were performed using MetaXL 5.3 (Epigear International, Sunrise Beach, Australia), which is an add-in for Microsoft Excel. RESULTS After pooling the publications from database searches, a total of 343 articles were found. After the first round, 44 articles were selected for full-text examined. From these, a total of 32 articles were finally included and reviewed (Table 1). Twenty-three studies were mutation screenings, seven were family studies, and two were case reports. Twelve studies were international collaborations that included Brazilian groups. Among the studies exclusively conducted in Brazil, only seven involved collaborations between groups in different regions of this country. According to the participation of Brazilian regions in these studies, patients in the Southeastern region were included in 25 studies, in the Southern region in nine studies, in the Central-western region in seven studies, in the Northern region in three studies and in the Northeastern region in three studies (Figure 1). Fifteen studies strictly only included patients with a family history of PD, and 16 studies strictly only included patients with EOPD. Among all these studies, 94 mutations were reported among approximately 2,872 Brazilian PD patients (3.2%). The mean age at evaluation and age at onset were 55.9 and 44.6 years, respectively. Nine genes were analyzed, and mutations in five genes were described (Table 2). Table 1. Main characteristics of 32 genetic studies involving Brazilian patients with PD Author, year Study design Sample size (Brazil) Gene analyzed Analysis method Results Reference Teive et al., 2001 Family study 10 SNCA PCR-RFLP No pathogenic mutations found [7] Rawal et al., 2003 Family study 4 PRKN Sequencing and PCR-RFLP PRKN: Ex4 del - 1, Ex6 del - 1, pAsn52* - 1 [8] Bertolli-Avella et al., 2005 Mutation screening 4 PRKN Sequencing and PCR-RFLP No pathogenic mutations found [9] Clarimon et al., 2005 Family study 6 PRKN Sequencing PRKN: Ex4 del - 1 [10] DiFonzo et al., 2005 Family study 9 LRRK2 Sequencing LRRK2: pG2019S - 1 [11] Bonifati et al., 2005 Mutation screening 8 PINK1 Sequencing No pathogenic mutations found [12] Khan et al., 2005 Family study 6 PRKN Sequencing PRKN: Ex4 del - 6 [13] Chien et al., 2006 Family study 10 PRKN, PINK1, DJ1 Sequencing and PCR-RFLP PRKN: IVS1+1G/T - 10 [14] DiFonzo et al., 2006 Family study 9 LRRK2 Sequencing No pathogenic mutations found [15] DiFonzo et al., 2007 Mutation screening 92 ATP13A2 Sequencing ATP13A2: pGly504Arg - 1 [16] Lesage et al., 2007 Mutation screening ND PRKN Sequencing PRKN: Prom+Ex1 del - 1 [17] Aguiar et al., 2008 Mutation screening 72 PRKN, LRRK2 Sequencing and qPCR LRRK2: pG2019S - 4; PRKN: Ex3 del/N58QfsX39 - 4, pK211N - 1, Ex11 del/A390EfsX6 - 1, c1286-3G>C - 1 [18] Munhoz et al., 2008 Mutation screening 83 LRRK2 PCR-RFLP LRRK2: p2019S - 6 [19] Pimentel et al., 2008 Mutation screening 147 LRRK2 Sequencing LRRK2: p2019S - 3 [20] Santos-Rebouças et al., 2008 Case report / series 1 LRRK2 PCR-RFLP LRRK2: p2019S - 1 [21] Godeiro-Junior et al., 2009 Mutation screening 60 PINK1 Sequencing No pathogenic mutations found [22] Barsottini et al., 2009 Mutation screening 119 PRKN, LRRK2 Sequencing and qPCR No pathogenic mutations found [23] Camargos et al., 2009 Mutation screening 53 SNCA, PRKN, LRRK2, PINK1 Sequencing LRRK2: pQ923H - 1; PRKN: Dup Ex5 - 1, pP253R - 1, pW54R - 1, pV3I - 1, pAsn52* - 2, pT240M - 2; PINK1: Ex7 del - 1 [24] Santos et al., 2010 Mutation screening 110 ATP13A2 Sequencing and PCR-RFLP No pathogenic mutations found [25] Abdalla-Carvalho et al., 2010 Mutation screening 197 LRRK2 Sequencing LRRK2: pT1410M - 4, pG2019 - 2, pC2139S - 1, pY2189C - 2 [26] Moura et al., 2012 Mutation screening 102 SNCA, PRKN, PINK1, DJ1 MLPA and qPCR PRKN: Ex4 del - 1, Ex5-6 del - 1, Dup Ex3 - 1, Dup Ex4 - 1 [27] Moura et al., 2013 Mutation screening 136 PRKN, PINK1 MLPA, allelic discrimination and PCR-RFLP PRKN: pT240M - 1 [28] Quadri et al., 2013 Mutation screening 31 SYNJ1 Sequencing No pathogenic mutations found [29] Chien et al., 2014 Mutation screening 100 LRRK2 PCR-RFLP No pathogenic mutations found [30] Bertucci-Filho et al., 2014 Mutation screening 69 PRKN, LRRK2 Sequencing LRRK2: pG2019S - 1; PRKN: Dup Ex2-3 - 1, pAsn52fs - 2, pArg256Cys - 1 [31] Longo et al., 2015 Mutation screening 154 SNCA PCR-RFLP No pathogenic mutations found [32] Pimentel et al., 2015 Mutation screening 549 SNCA Sequencing and qPCR No pathogenic mutations found [33] Spitz et al., 2015 Case report / series 1 LRRK2 Sequencing and PCR-RFLP LRRK2: pG2019S - 1 [34] Olgiati et al., 2016 Mutation screening 39 DNAJC6 Sequencing DNAJC6: pThr741= - 2, c1468+83del - 1, c2038+3A>G - 1 [35] Abreu et al., 2016 Mutation screening 141 SNCA, LRRK2, VPS35 Allelic discrimination and sequencing LRRK2: pG2019S - 5 [36] Cornejo-Olivas et al., 2017 Mutation screening 433 LRRK2 Allelic discrimination and sequencing LRRK2: pG2019S - 6, pR1441C - 1 [37] Silva et al., 2017 Mutation screening 131 LRRK2 Sequencing and PCR-RFLP LRRK2: pG2019S - 5 [38] MLPA: Multiplex ligation-dependent probe amplification; ND: Not described; PCR-RFLP: Polymerase chain reaction with restriction fragment length polymorphism; qPCR: Quantitative polymerase chain reaction. Figure 1. Distribution of monogenic forms of PD described in Brazil. A: Distribution of studies on monogenic forms of PD in Brazil according to states. B: Distribution of LRRK2 and PRKN mutations in Brazil according to regions (depicted in different shades of gray). Studies are represented by symbols, according to the type of study design. Ancestry proportions of each region are represented in pie charts, based on Moura et al., 20154. Table 2. List of genes investigated and mutations identified in Brazilian patients with PD. Genes investigated in Brazilian patients with PD Genes with mutation identified in Brazilian patients with PD ATP13A2 ATP13A2 DJ1 DNAJC6 DNAJC6 LRRK2 LRRK2 PINK1 PINK1 PRKN PRKN SNCA SYNJ1 VPS35 Fifteen studies assessed the prevalence of LRRK2 mutations among 1,556 patients, finding a total of 40 patients (2.5%) carrying LRRK2 mutations. Four of these studies only included patients with familial PD (total of 233 patients; 14.9% of all patients screened for LRRK2 mutations), and five studies only included patients with EOPD (total of 410 patients; 26.3% of all patients screened for LRRK2 mutations). There were no homozygous or compound heterozygous mutations. The mean age at onset was 49.9 years (95% CI, 45.1-54.6) and a positive family history was found among 45.4% of the patients with PD carrying LRRK2 mutations. The most common mutation in the LRRK2 gene was p.G2019S (n = 35), followed by p.Y2189C (n = 2) and p.C2139S, p.R1441C and p.Q923H (each of these last mutations was detected in one patient) (Figure 2). However, nine studies explored only the p.G2019S mutation, and three studies sequenced the whole LRRK2 gene, thus probably overestimating the frequency of this mutation in Brazilian patients with PD. Only p.G2019S and p.R1441C were classified as definitely pathogenic mutations, and the other mutations (p.Y2189C, p.C2139S and p.Q923H) were classified as variants of uncertain significance. In accordance with the methodology described above, we selected eight studies for meta-analysis (n = 1,257). The random-effect model showed that the weighted pooled prevalence of LRRK2 mutations in Brazilian patients with PD was 3.5% (95% CI, 2.2%-5.0%), with moderate heterogeneity between the studies analyzed (I2 = 37.4%; p = 0.13) (Figure 3A). Comparing only the studies that included strictly EOPD or familial PD patients, the weighted pooled prevalence of LRRK2 mutations was 5.4% (95% CI, 2.7%-9.0%) in three studies that included strictly EOPD patients (n = 208) (Figure 3B), and 5% (95% CI, 1.9%-9.2%) in two studies that included strictly familial PD patients (n = 224) (Figure 3C). Figure 2. Schematic representation of LRRK2 protein domains, and locations of mutations described in Brazilian patients with PD, adapted from the website of the Movement Disorder Society Genetic Mutation Database5. Arrows indicate the locations of point mutations. Definitely pathogenic mutations are indicated in red letters and variants of uncertain significance in black letters. Figure 3. Forest plot of prevalence of LRRK2 mutation-positive Brazilian patients with PD and 95% confidence intervals for each study included in the meta-analysis. A: Analysis with all studies. B: Analysis with studies that strictly included early-onset PD cases. C: Analysis with studies that strictly included familial PD cases. Right-hand column shows per-study prevalence of mutation-positive cases for LRRK2 (%), 95% confidence intervals and the weighting (%) of each study. The overall weighted prevalence in the random-effects model is denoted by a blue diamond and dotted line. Blue squares are in proportion to the weighting of each study, and blue bars show confidence intervals. Twelve studies assessed the prevalence of PRKN mutations among a total of 576 patients, finding a total of 48 patients (8.3%) carrying PRKN mutations. Five of these studies only included patients with familial PD (total of 25 patients; 4.3% of all patients screened for PRKN mutations), and eight studies only included patients with EOPD (total of 559 patients; 97% of all patients screened for PRKN mutations). Among these mutations, 43.7% were homozygous and 12.5% were compound heterozygous. The mean age at onset was 31.8 years (95% CI, 28.5-35.1) and there was a positive family history among 66.6% of the patients carrying PRKN mutations, including copy number variations, single nucleotide variants and frameshift mutations (Figure 4). The most common mutations in PRKN were IVS1+1G/T (n = 10) and a deletion in exon 4 (n = 9). Two mutations were classified as probably pathogenic (p.R256C and c.1286-3G>C), and four as variants of uncertain significance (IVS1+1G/T, p.P253R, p.V3I and p.W54R) due their rarity; all other mutations were classified as definitely pathogenic. We selected four studies for meta-analysis; these studies included strictly EOPD patients, and none included only familial PD patients (n = 296). The random-effect model showed that the weighted pooled prevalence of PRKN mutations in Brazilian EOPD patients was 9.3% (95% CI, 4.4%-15.6%), with high heterogeneity between the studies analyzed (I2 = 62.9%; p = 0.04) (Figure 5). Figure 4. Schematic representation of Parkin protein domains, and locations of mutations described in Brazilian patients with PD, adapted from the website of the Movement Disorder Society Genetic Mutation Database5. Arrows indicate the locations of point mutations, and horizontal lines indicate the locations of copy number variations (deletions and duplications). Definitely pathogenic mutations are indicated in red letters, probably pathogenic mutations in blue letters and variants of uncertain significance in black letters. Figure 5. Forest plot of prevalence of PRKN mutation-positive early-onset Brazilian patients with PD and 95% confidence intervals for each study included in the meta-analysis. Right-hand column shows per-study prevalence of mutation-positive cases for PRKN (%), 95% confidence intervals and the weighting (%) of each study. The overall weighted prevalence in the random-effects model is denoted by a blue diamond and dotted line. Blue squares are in proportion to the weighting of each study, and blue bars show confidence intervals. There were descriptions of mutations in other three genes: four patients with DNAJC6 mutations (two patients homozygous for p.T741=, one with compound heterozygosity for c.1468+83del and one with compound heterozygosity for c.2038+3A>G), one patient with PINK1 mutation (homozygous deletion in exon 7) and one patient with an ATP13A2 homozygous mutation (p.G504R). The PINK1 deletion in exon 7 and ATP13A2 p.G504R was classified as probably pathogenic, DNAJC6 p.T741= as possibly pathogenic and DNAJC6 c.1468+83del and c.2038+3A>G as variants of uncertain significance. DISCUSSION We found in this systematic review that there is a significant number of studies on monogenic forms of PD in Brazilian patients, in which around 3,000 patients were evaluated. Most of these studies were mutation screenings. Mutations in nine genes related to PD were investigated: SNCA, PRKN, LRRK2, PINK1, DJ1, VPS35, ATP13A2, DNAJC6 and SYNJ1; mutations were found in five of them: PRKN, LRRK2, PINK1, ATP13A2 and DNAJC6. The two genes most studied in Brazilian patients were PRKN and LRRK2. This finding was expected, as these monogenic forms of PD are the most common forms worldwide1. The LRRK2 p.G2019S point mutation is the most common associated variant that causes monogenic PD2, and it also seems to be the most important cause of LRRK2 PD in the Brazilian population to date. We estimated that the weighted pooled prevalence of LRRK2 mutations was 3.5% among all the Brazilian patients evaluated here, and 5% among familial PD cases. However, considering the low level of inclusion of familial PD patients, and that most studies only screened for the p.G2019S mutation, these prevalences may be imprecise. These Brazilian findings are similar to worldwide data, in which LRRK2 p.G2019S point mutations are present in 1-5% of patients with sporadic PD2,39. Autosomal recessive homozygous or compound heterozygous loss-of-function mutations were identified in four genes (PRKN, PINK1, ATP13A2 and DNAJC6) in Brazilian patients. PRKN was the most commonly identified gene with pathological mutations in EOPD patients. In the Brazilian population, as was expected, presence of a family history of PD and earlier age of onset were associated with PRKN mutations. Two-thirds of these patients with PD carrying PRKN mutations in Brazil reported having a family history. As expected, there were different types of mutations in PRKN, including copy number, single nucleotide and frameshift variants. The weighted pooled prevalence in Brazilian EOPD patients (9.3%) was similar to the estimated global prevalence of PRKN mutations in a previous systematic review on EOPD cases (8.6%; 95% CI, 6.0%-12.4%)40. SNCA mutations have been found in many countries, comprising 0.2% of sporadic and 1-2% of familial PD cases1, but no such patients have been described in Brazil, even though six studies explored this. The lack of mutations in VPS35, DJ1 and SYNJ1 among Brazilian patients was not surprising, since these are rare causes of PD1, and only three studies explored these genes. Despite the significant number of studies, it was not possible to accurately estimate the epidemiology of monogenic forms of PD in Brazil. We noted that selection bias was present and that only small numbers of patients were included in most studies. Most of the genetic analyses were among individuals in the southern regions of the country, with a strong contribution from European ancestry, which may have given rise to bias of representation within the Brazilian population (the Northern region has the highest proportion of Amerindian ancestry, and the Northeastern region has the highest proportion of African ancestry) (Figure 1B)4. Therefore, our first conclusion from this systematic review is that there is a lack of robust Brazilian epidemiological studies on the genetics of PD. We noticed that the level of interactions between Brazilian research groups in different regions of Brazil was low among these genetic studies. It was more common for individual Brazilian groups to participate in collaborative international studies. Genetic diversity is a major challenge in the field of PD genetics. Like other scientific fields, the majority of the research has been done on individuals with mainly European ancestry. One potential bias in Brazilian studies is that almost all of them were conducted in dedicated tertiary-level referral centers and thus included patients with relatively high a priori likelihood of monogenic disorders. Another limitation of our analysis was that data from the same patient could have been described in different publications, and this might have caused an overlap between studies. Unfortunately, we were unable to contact the researchers involved in all the original studies in order to gain access to raw data. In summary, this systematic review showed that there is a lack of robust Brazilian epidemiological studies on the genetics of PD. To date, only five genes associated with monogenic PD have been identified in Brazilian patients with PD (PRKN, LRRK2, PINK1, ATP13A2 and DNAJC6). Studies with larger samples are needed in order to more precisely estimate the frequency of monogenic PD forms in Brazil, a country of continental size and huge genetic variability. We also identified regions of this country that are underrepresented with regard to genetic studies, and we would therefore urge increased representation of these regions in future studies. Acknowledgements We would like to thank Prof. Márcia Mattos Gonçalves Pimentel, PhD (Universidade do Estado do Rio de Janeiro), for contributing with data from original publications. References 1. Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol (Paris). 2018 Nov;174(9):628-43. https://doi.org/10.1016/j.neurol.2018.08.004 Lunati A Lesage S Brice A The genetic landscape of Parkinson’s disease Rev Neurol (Paris) 2018 174 9 628 643 https://doi.org/10.1016/j.neurol.2018.08.004 2. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, Genotype, and Worldwide Genetic Penetrance of LRRK2-associated Parkinson's Disease: A Case-Control Study. Lancet Neurol. 2008 Jul;7(7):583-90. https://doi.org/10.1016/s1474-4422(08)70117-0 Healy DG Falchi M O'Sullivan SS Bonifati V Durr A Bressman S Phenotype, Genotype, and Worldwide Genetic Penetrance of LRRK2-associated Parkinson's Disease: A Case-Control Study Lancet Neurol 2008 7 7 583 590 https://doi.org/10.1016/s1474-4422(08)70117-0 3. Brazilian Institute of Geography and Statistics [Internet]. Projections of population in Brazil and Federal Units per sex and age: 2010-2060. Rio de Janeiro: IBGE; [cited 2020 Jul 29]. Available from: Available from: https://www.ibge.gov.br/estatisticas/sociais/populacao/9109-projecao-da-populacao.html?=&t=resultados Brazilian Institute of Geography and Statistics Internet Projections of population in Brazil and Federal Units per sex and age: 2010-2060 Rio de Janeiro IBGE 2020 Jul 29 Available from: https://www.ibge.gov.br/estatisticas/sociais/populacao/9109-projecao-da-populacao.html?=&t=resultados 4. Moura RR, Coelho AVC, Balbino VQ, Crovella S, Brandão LAC. Meta-analysis of Brazilian Genetic Admixture and Comparison with Other Latin America Countries. Am J Hum Biol. 2015 Sept-Oct;27(5):674-80. https://doi.org/10.1002/ajhb.22714 Moura RR Coelho AVC Balbino VQ Crovella S Brandão LAC Meta-analysis of Brazilian Genetic Admixture and Comparison with Other Latin America Countries Am J Hum Biol 2015 27 5 674 680 https://doi.org/10.1002/ajhb.22714 5. Klein C, Hattori N, Marras C. Closing data gaps in genotype-phenotype correlations of monogenic Parkinson's disease. J Parkinsons Dis. 2018;8(Suppl 1):S25-30. https://doi.org/10.3233/jpd-181505 Klein C Hattori N Marras C Closing data gaps in genotype-phenotype correlations of monogenic Parkinson's disease J Parkinsons Dis 2018 8 1 S25 S30 https://doi.org/10.3233/jpd-181505 6. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018 Jan;46(D1):D1062-7. https://doi.org/10.1093/nar/gkx1153 Landrum MJ Lee JM Benson M Brown GR Chao C Chitipiralla S : improving access to variant interpretations and supporting evidence Nucleic Acids Res 2018 46 D1 D1062 D1067 https://doi.org/10.1093/nar/gkx1153 7. Teive HA, Raskin S, Iwamoto FM, Germiniani FM, Baran MH, Werneck LC, et al. The G209A Mutation in the Alpha-Synuclein Gene in Brazilian Families With Parkinson's Disease. Arq Neuropsiquiatr. 2001 Sept;59(3-B):722-4. https://doi.org/10.1590/s0004-282x2001000500013 Teive HA Raskin S Iwamoto FM Germiniani FM Baran MH Werneck LC The G209A Mutation in the Alpha-Synuclein Gene in Brazilian Families With Parkinson's Disease Arq Neuropsiquiatr 2001 59 3-B 722 724 https://doi.org/10.1590/s0004-282x2001000500013 8. Rawal N, Periquet M, Lohmann E, Lücking CB, Teive HA, Ambrosio G, et al. New Parkin Mutations and Atypical Phenotypes in Families with Autosomal Recessive Parkinsonism. Neurology. 2003 Apr;60(8):1378-81. https://doi.org/10.1212/01.wnl.0000056167.89221.be Rawal N Periquet M Lohmann E Lücking CB Teive HA Ambrosio G New Parkin Mutations and Atypical Phenotypes in Families with Autosomal Recessive Parkinsonism Neurology 2003 60 8 1378 1381 https://doi.org/10.1212/01.wnl.0000056167.89221.be 9. Bertoli-Avella AM, Giroud-Benitez JL, Akyol A, Barbosa E, Schaap O, van der Linde HC, et al. Novel Parkin Mutations Detected in Patients With Early-Onset Parkinson's Disease. Mov Disord. 2005 Apr;20(4):424-31. https://doi.org/10.1002/mds.20343 Bertoli-Avella AM Giroud-Benitez JL Akyol A Barbosa E Schaap O van der Linde HC Novel Parkin Mutations Detected in Patients With Early-Onset Parkinson's Disease Mov Disord 2005 20 4 424 431 https://doi.org/10.1002/mds.20343 10. Clarimon J, Johnson J, Dogu O, Horta W, Khan N, Lees AJ, et al. Defining the Ends of Parkin Exon 4 Deletions in Two Different Families With Parkinson's Disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb;133B(1):120-3. Clarimon J Johnson J Dogu O Horta W Khan N Lees AJ Defining the Ends of Parkin Exon 4 Deletions in Two Different Families With Parkinson's Disease Am J Med Genet B Neuropsychiatr Genet 2005 133B 1 120 123 11. Di Fonzo A, Rohé CF, Ferreira J, Chien HF, Vacca L, Stocchi F, et al. A Frequent LRRK2 Gene Mutation Associated with Autosomal Dominant Parkinson's Disease. Lancet. 2005 Jan-Feb;365(9457):412-5. https://doi.org/10.1016/s0140-6736(05)17829-5 Di Fonzo A Rohé CF Ferreira J Chien HF Vacca L Stocchi F A Frequent LRRK2 Gene Mutation Associated with Autosomal Dominant Parkinson's Disease Lancet 2005 365 9457 412 415 https://doi.org/10.1016/s0140-6736(05)17829-5 12. Bonifati V, Rohé CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C, et al. Early-onset Parkinsonism Associated With PINK1 Mutations: Frequency, Genotypes, and Phenotypes. Neurology. 2005 Jul;65(1):87-95. https://doi.org/10.1212/01.wnl.0000167546.39375.82 Bonifati V Rohé CF Breedveld GJ Fabrizio E De Mari M Tassorelli C Early-onset Parkinsonism Associated With PINK1 Mutations: Frequency, Genotypes, and Phenotypes Neurology 2005 65 1 87 95 https://doi.org/10.1212/01.wnl.0000167546.39375.82 13. Khan NL, Horta W, Eunson L, Graham E, Johnson JO, Chang S, et al. Parkin Disease in a Brazilian Kindred: Manifesting Heterozygotes and Clinical Follow-Up Over 10 Years. Mov Disord. 2005 Apr;20(4):479-84. https://doi.org/10.1002/mds.20335 Khan NL Horta W Eunson L Graham E Johnson JO Chang S Parkin Disease in a Brazilian Kindred: Manifesting Heterozygotes and Clinical Follow-Up Over 10 Years Mov Disord 2005 20 4 479 484 https://doi.org/10.1002/mds.20335 14. Chien HF, Rohé CF, Costa MDL, Breedveld GJ, Oostra BA, Barbosa ER, et al. Early-onset Parkinson's Disease Caused by a Novel Parkin Mutation in a Genetic Isolate From North-Eastern Brazil. Neurogenetics. 2006 Mar;7(1):13-9. https://doi.org/10.1007/s10048-005-0017-x Chien HF Rohé CF Costa MDL Breedveld GJ Oostra BA Barbosa ER Early-onset Parkinson's Disease Caused by a Novel Parkin Mutation in a Genetic Isolate From North-Eastern Brazil Neurogenetics 2006 7 1 13 19 https://doi.org/10.1007/s10048-005-0017-x 15. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohé CF, et al. Comprehensive Analysis of the LRRK2 Gene in Sixty Families With Parkinson's Disease. Eur J Hum Genet. 2006 Mar;14(3):322-31. https://doi.org/10.1038/sj.ejhg.5201539 Di Fonzo A Tassorelli C De Mari M Chien HF Ferreira J Rohé CF Comprehensive Analysis of the LRRK2 Gene in Sixty Families With Parkinson's Disease Eur J Hum Genet 2006 14 3 322 331 https://doi.org/10.1038/sj.ejhg.5201539 16. Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, et al. ATP13A2 Missense Mutations in Juvenile Parkinsonism and Young Onset Parkinson Disease. Neurology. 2007 May;68(19):1557-62. https://doi.org/10.1212/01.wnl.0000260963.08711.08 Di Fonzo A Chien HF Socal M Giraudo S Tassorelli C Iliceto G ATP13A2 Missense Mutations in Juvenile Parkinsonism and Young Onset Parkinson Disease Neurology 2007 68 19 1557 1562 https://doi.org/10.1212/01.wnl.0000260963.08711.08 17. Lesage S, Magali P, Lohmann E, Lacomblez L, Teive H, Janin S, et al. Deletion of the Parkin and PACRG Gene Promoter in Early-Onset Parkinsonism. Hum Mutat. 2007 Jan;28(1):27-32. https://doi.org/10.1002/humu.20436 Lesage S Magali P Lohmann E Lacomblez L Teive H Janin S Deletion of the Parkin and PACRG Gene Promoter in Early-Onset Parkinsonism Hum Mutat 2007 28 1 27 32 https://doi.org/10.1002/humu.20436 18. Aguiar PC, Lessa PS, Godeiro Jr C, Barsottini O, Felício AC, Borges V, et al. Genetic and Environmental Findings in Early-Onset Parkinson's Disease Brazilian Patients. Mov Disord. 2008 Jul;23(9):1228-33. https://doi.org/10.1002/mds.22032 Aguiar PC Lessa PS Godeiro C Jr Barsottini O Felício AC Borges V Genetic and Environmental Findings in Early-Onset Parkinson's Disease Brazilian Patients Mov Disord 2008 23 9 1228 1233 https://doi.org/10.1002/mds.22032 19. Munhoz RP, Wakutani Y, Marras C, Teive HA, Raskin S, Werneck LC, et al. The G2019S LRRK2 Mutation in Brazilian Patients With Parkinson's Disease: Phenotype in Monozygotic Twins. Mov Disord. 2008 Jan;23(2):290-4. https://doi.org/10.1002/mds.21832 Munhoz RP Wakutani Y Marras C Teive HA Raskin S Werneck LC The G2019S LRRK2 Mutation in Brazilian Patients With Parkinson's Disease: Phenotype in Monozygotic Twins Mov Disord 2008 23 2 290 294 https://doi.org/10.1002/mds.21832 20. Pimentel MMG, Moura KCV, Abdalla CB, Pereira JS, Rosso ALZ, Nicaretta DH, et al. A Study of LRRK2 Mutations and Parkinson's Disease in Brazil. Neurosci Lett. 2008 Mar;433(1):17-21. https://doi.org/10.1016/j.neulet.2007.12.033 Pimentel MMG Moura KCV Abdalla CB Pereira JS Rosso ALZ Nicaretta DH A Study of LRRK2 Mutations and Parkinson's Disease in Brazil Neurosci Lett 2008 433 1 17 21 https://doi.org/10.1016/j.neulet.2007.12.033 21. Santos-Rebouças CB, Abdalla CB, Baldi FJR, Martins PA, Corrêa JC, Gonçalves AP, et al. Co-occurrence of Sporadic Parkinsonism and Late-Onset Alzheimer's Disease in a Brazilian Male With the LRRK2 p.G2019S Mutation. Genet Test. 2008 Dec;12(4):471-3. https://doi.org/10.1089/gte.2008.0042 Santos-Rebouças CB Abdalla CB Baldi FJR Martins PA Corrêa JC Gonçalves AP Co-occurrence of Sporadic Parkinsonism and Late-Onset Alzheimer's Disease in a Brazilian Male With the LRRK2 p.G2019S Mutation Genet Test 2008 12 4 471 473 https://doi.org/10.1089/gte.2008.0042 22. Godeiro Jr C, Aguiar PMC, Felício AC, Barsottini OGP, Silva SMA, Borges V, et al. PINK1 Polymorphism IVS1-7 A-->G, Exposure to Environmental Risk Factors and Anticipation of Disease Onset in Brazilian Patients With Early-Onset Parkinson's Disease. Neurosci Lett. 2010 Jan;469(1):155-8. https://doi.org/10.1016/j.neulet.2009.11.064 Godeiro C Jr Aguiar PMC Felício AC Barsottini OGP Silva SMA Borges V PINK1 Polymorphism IVS1-7 A-->G, Exposure to Environmental Risk Factors and Anticipation of Disease Onset in Brazilian Patients With Early-Onset Parkinson's Disease Neurosci Lett 2010 469 1 155 158 https://doi.org/10.1016/j.neulet.2009.11.064 23. Barsottini OGP, Felício AC, Aguiar PC, Godeiro-Junior C, Shih MC, Hoexter MQ, et al. Clinical and Molecular Neuroimaging Characteristics of Brazilian Patients With Parkinson's Disease and Mutations in PARK2 or PARK8 Genes. Arq Neuropsiquiatr. 2009 Mar;67(1):7-11. https://doi.org/10.1590/s0004-282x2009000100003 Barsottini OGP Felício AC Aguiar PC Godeiro-Junior C Shih MC Hoexter MQ Clinical and Molecular Neuroimaging Characteristics of Brazilian Patients With Parkinson's Disease and Mutations in PARK2 or PARK8 Genes Arq Neuropsiquiatr 2009 67 1 7 11 https://doi.org/10.1590/s0004-282x2009000100003 24. Camargos ST, Dornas LO, Momeni P, Lees A, Hardy J, Singleton A, et al. Familial Parkinsonism and Early Onset Parkinson's Disease in a Brazilian Movement Disorders Clinic: Phenotypic Characterization and Frequency of SNCA, PRKN, PINK1, and LRRK2 Mutations. Mov Disord. 2009 Apr;24(5):662-6. https://doi.org/10.1002/mds.22365 Camargos ST Dornas LO Momeni P Lees A Hardy J Singleton A Familial Parkinsonism and Early Onset Parkinson's Disease in a Brazilian Movement Disorders Clinic: Phenotypic Characterization and Frequency of SNCA, PRKN, PINK1, and LRRK2 Mutations Mov Disord 2009 24 5 662 666 https://doi.org/10.1002/mds.22365 25. Santos AV, Pestana CP, Diniz KRS, Campos M, Abdalla-Carvalho CB, Rosso ALZ, et al. Mutational Analysis of GIGYF2, ATP13A2 and GBA Genes in Brazilian Patients With Early-Onset Parkinson's Disease. Neurosci Lett. 2010 Nov;485(2):121-4. https://doi.org/10.1016/j.neulet.2010.08.083 Santos AV Pestana CP Diniz KRS Campos M Abdalla-Carvalho CB Rosso ALZ Mutational Analysis of GIGYF2, ATP13A2 and GBA Genes in Brazilian Patients With Early-Onset Parkinson's Disease Neurosci Lett 2010 485 2 121 124 https://doi.org/10.1016/j.neulet.2010.08.083 26. Abdalla-Carvalho CB, Santos-Rebouças CB, Guimarães BC, Campos M, Pereira JS, Rosso ALZ, et al. Genetic Analysis of LRRK2 Functional Domains in Brazilian Patients With Parkinson's Disease. Eur J Neurol. 2010 Dec;17(12):1479-81. https://doi.org/10.1111/j.1468-1331.2010.03039.x Abdalla-Carvalho CB Santos-Rebouças CB Guimarães BC Campos M Pereira JS Rosso ALZ Genetic Analysis of LRRK2 Functional Domains in Brazilian Patients With Parkinson's Disease Eur J Neurol 2010 17 12 1479 1481 https://doi.org/10.1111/j.1468-1331.2010.03039.x 27. Moura KCV, Campos Junior M, Rosso ALZ, Nicaretta DH, Pereira JS, Silva DJ, et al. Exon Dosage Variations in Brazilian Patients With Parkinson's Disease: Analysis of SNCA, PARKIN, PINK1 and DJ-1 Genes. Dis Markers. 2012;32(3):173-8. https://doi.org/10.3233/dma-2011-0873 Moura KCV Campos M Junior Rosso ALZ Nicaretta DH Pereira JS Silva DJ Exon Dosage Variations in Brazilian Patients With Parkinson's Disease: Analysis of SNCA, PARKIN, PINK1 and DJ-1 Genes Dis Markers 2012 32 3 173 178 https://doi.org/10.3233/dma-2011-0873 28. Moura KCV, Campos Junior M, Rosso ALZ, Nicaretta DH, Pereira JS, Silva DJ, et al. Genetic Analysis of PARK2 and PINK1 Genes in Brazilian Patients with Early-Onset Parkinson's Disease. Dis Markers. 2013;35(3):181-5. https://doi.org/10.1155/2013/597158 Moura KCV Campos M Junior Rosso ALZ Nicaretta DH Pereira JS Silva DJ Genetic Analysis of PARK2 and PINK1 Genes in Brazilian Patients with Early-Onset Parkinson's Disease Dis Markers 2013 35 3 181 185 https://doi.org/10.1155/2013/597158 29. Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, et al. Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. Hum Mutat. 2013 Sept;34(9):1208-15. https://doi.org/10.1002/humu.22373 Quadri M Fang M Picillo M Olgiati S Breedveld GJ Graafland J Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism Hum Mutat 2013 34 9 1208 1215 https://doi.org/10.1002/humu.22373 30. Chien HF, Figueiredo TR, Hollaender MA, Tofoli F, Takada LT, Pereira LV, et al. Frequency of the LRRK2 G2019S Mutation in Late-Onset Sporadic Patients With Parkinson's Disease. Arq Neuropsiquiatr. 2014 May;72(5):356-9. https://doi.org/10.1590/0004-282x20140019 Chien HF Figueiredo TR Hollaender MA Tofoli F Takada LT Pereira LV Frequency of the LRRK2 G2019S Mutation in Late-Onset Sporadic Patients With Parkinson's Disease Arq Neuropsiquiatr 2014 72 5 356 359 https://doi.org/10.1590/0004-282x20140019 31. Bertucci Filho D, Munhoz RP, Lesage S, Brice A, Raskin S, Teive HAG. Prevalence and Phenotype of patients with PARK2 or PARK8 Gene Mutations in an Early-Onset Parkinsonism Brazilian Cohort. J J Neur Neurosci. 2014;1(2):003. Bertucci D Filho Munhoz RP Lesage S Brice A Raskin S Teive HAG Prevalence and Phenotype of patients with PARK2 or PARK8 Gene Mutations in an Early-Onset Parkinsonism Brazilian Cohort J J Neur Neurosci 2014 1 2 003 32. Longo GS, Pinhel MAS, Gregório ML, Oliveira BAP, Quinhoneiro DCG, Tognola WA, et al. Alpha-synuclein A53T Mutation Is Not Frequent on a Sample of Brazilian Parkinson's Disease Patients. Arq Neuropsiquiatr. 2015 Jun;73(6):506-9. https://doi.org/10.1590/0004-282x20150032 Longo GS Pinhel MAS Gregório ML Oliveira BAP Quinhoneiro DCG Tognola WA Alpha-synuclein A53T Mutation Is Not Frequent on a Sample of Brazilian Parkinson's Disease Patients Arq Neuropsiquiatr 2015 73 6 506 509 https://doi.org/10.1590/0004-282x20150032 33. Pimentel MMG, Rodrigues FC, Leite MAA, Campos Júnior M, Rosso AL, Nicaretta DH, et al. Parkinson Disease: α-synuclein Mutational Screening and New Clinical Insight Into the p.E46K Mutation. Parkinsonism Relat Disord. 2015 Jun;21(6):586-9. https://doi.org/10.1016/j.parkreldis.2015.03.011 Pimentel MMG Rodrigues FC Leite MAA Campos M Júnior Rosso AL Nicaretta DH Parkinson Disease: α-synuclein Mutational Screening and New Clinical Insight Into the p.E46K Mutation Parkinsonism Relat Disord 2015 21 6 586 589 https://doi.org/10.1016/j.parkreldis.2015.03.011 34. Spitz M, Pereira JS, Nicareta DH, Abreu GM, Bastos EF, Seixas TL, et al. Association of LRRK2 and GBA Mutations in a Brazilian Family With Parkinson's Disease. Parkinsonism Relat Disord. 2015 Jul;21(7):825-6. https://doi.org/10.1016/j.parkreldis.2015.03.029 Spitz M Pereira JS Nicareta DH Abreu GM Bastos EF Seixas TL Association of LRRK2 and GBA Mutations in a Brazilian Family With Parkinson's Disease Parkinsonism Relat Disord 2015 21 7 825 826 https://doi.org/10.1016/j.parkreldis.2015.03.029 35. Olgiati S, Quadri M, Fang M, Rood JPMA, Saute JA, Chien HF, et al. DNAJC6 Mutations Associated with Early-Onset Parkinson's Disease. Ann Neurol. 2016 Feb;79(2):244-56. https://doi.org/10.1002/ana.24553 Olgiati S Quadri M Fang M Rood JPMA Saute JA Chien HF DNAJC6 Mutations Associated with Early-Onset Parkinson's Disease Ann Neurol 2016 79 2 244 256 https://doi.org/10.1002/ana.24553 36. Abreu GM, Valença DCT, Campos Júnior M, Silva CP, Pereira JS, Leite MAA, et al. Autosomal Dominant Parkinson's Disease: Incidence of Mutations in LRRK2, SNCA, VPS35 and GBA Genes in Brazil. Neurosci Lett. 2016 Dec;635:67-70. https://doi.org/10.1016/j.neulet.2016.10.040 Abreu GM Valença DCT Campos M Júnior Silva CP Pereira JS Leite MAA Autosomal Dominant Parkinson's Disease: Incidence of Mutations in LRRK2, SNCA, VPS35 and GBA Genes in Brazil Neurosci Lett 2016 635 67 70 https://doi.org/10.1016/j.neulet.2016.10.040 37. Cornejo-Olivas M, Torres L, Velit-Salazar MR, Inca-Martinez M, Mazzetti P, Cosentino C, et al. Variable Frequency of LRRK2 Variants in the Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD), a Case of Ancestry. NPJ Parkinsons Dis. 2017 Jun;3:19. https://doi.org/10.1038/s41531-017-0020-6 Cornejo-Olivas M Torres L Velit-Salazar MR Inca-Martinez M Mazzetti P Cosentino C Variable Frequency of LRRK2 Variants in the Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD), a Case of Ancestry NPJ Parkinsons Dis 2017 3 19 https://doi.org/10.1038/s41531-017-0020-6 38. Silva CP, Abreu GM, Acero PHC, Campos Júnior M, Pereira JS, Ramos SRA, et al. Clinical Profiles Associated With LRRK2 and GBA Mutations in Brazilians With Parkinson's Disease. J Neurol Sci. 2017 Oct;381:160-4. https://doi.org/10.1016/j.jns.2017.08.3249 Silva CP Abreu GM Acero PHC Campos M Júnior Pereira JS Ramos SRA Clinical Profiles Associated With LRRK2 and GBA Mutations in Brazilians With Parkinson's Disease J Neurol Sci 2017 381 160 164 https://doi.org/10.1016/j.jns.2017.08.3249 39. Guedes LC, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord. 2010 May;16(4):237-42. https://doi.org/10.1016/j.parkreldis.2009.11.004 Guedes LC Ferreira JJ Rosa MM Coelho M Bonifati V Sampaio C Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review Parkinsonism Relat Disord 2010 16 4 237 242 https://doi.org/10.1016/j.parkreldis.2009.11.004 40. Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MDW, Misbahuddin A, et al. Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease. Mov Disord. 2012 Oct;27(12):1522-9. https://doi.org/10.1002/mds.25132 Kilarski LL Pearson JP Newsway V Majounie E Knipe MDW Misbahuddin A Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease Mov Disord 2012 27 12 1522 1529 https://doi.org/10.1002/mds.25132